Showing results (211-220 of 230) with videos related to

Sort By:
Pageof 23
Plos One|August 23, 2013
A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related testsFrederick A Schroeder, Michael C Lewis, Daniel M Fass, et al.
Science Translational Medicine|May 22, 2020
Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndromePatrick K McCamphill, Laura J Stoppel, Rebecca K Senter, et al.
Scientific Reports|April 28, 2021
HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia/reperfusion injuryDavid D Aufhauser, Paul Hernandez, Seth J Concors, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Cancer Cell|November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stabilitySrividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
ACS Chemical Biology|December 8, 2015
An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell ProtectionFlorence F Wagner, Morten Lundh, Taner Kaya, et al.
ACS Chemical Biology|August 5, 2014
An unbiased approach to identify endogenous substrates of "histone" deacetylase 8David E Olson, Namrata D Udeshi, Noah A Wolfson, et al.
The Journal of Biological Chemistry|September 9, 2006
C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinasesYuh-Ping Chong, Andrew S Chan, Khai-Chew Chan, et al.
Chemical Science|February 3, 2015
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition EnhancersF F Wagner, Y-L Zhang, D M Fass, et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids|May 4, 2019
2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 diseaseJessica Davidson, Elizabeth Molitor, Samantha Moores, et al.
Pageof 23